Wall Street brokerages predict that Seelos Therapeutics Inc (NASDAQ:SEEL) will announce earnings per share (EPS) of ($0.20) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Seelos Therapeutics’ earnings. Seelos Therapeutics reported earnings per share of ($4.20) during the same quarter last year, which would suggest a positive year-over-year growth rate of 95.2%. The firm is expected to report its next quarterly earnings results on Thursday, May 30th.
According to Zacks, analysts expect that Seelos Therapeutics will report full-year earnings of ($0.88) per share for the current year, with EPS estimates ranging from ($1.03) to ($0.72). For the next year, analysts anticipate that the business will post earnings of ($1.10) per share, with EPS estimates ranging from ($1.11) to ($1.09). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Seelos Therapeutics.
SEEL has been the subject of a number of analyst reports. HC Wainwright initiated coverage on shares of Seelos Therapeutics in a research report on Friday, May 10th. They set a “buy” rating and a $4.00 target price for the company. Roth Capital initiated coverage on shares of Seelos Therapeutics in a research report on Tuesday, May 14th. They set a “buy” rating and a $8.00 target price for the company.
Shares of SEEL remained flat at $$2.64 during mid-day trading on Friday. 135,695 shares of the stock traded hands, compared to its average volume of 3,159,903. Seelos Therapeutics has a 52-week low of $1.32 and a 52-week high of $17.40.
Seelos Therapeutics Company Profile
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.
See Also: What is the LIBOR?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.